Document is current
Any future updates will be listed below
-
Authors
Corazolla, Eleonore M.
Eskes, Eline C. B.
Veldwijk, Jorien
Brands, Marion M. M. G.
Dekker, Hanka
van de Mheen, Erica
Langeveld, Mirjam
Hollak, Carla E. M.
Sjouke, Barbara https://orcid.org/0000-0001-8162-9684
-
Funding
Funding for this research was provided by:
Amsterdam University Medical Centers
- License Information
-
More Information
Article History
Received: 5 September 2023
Accepted: 18 September 2024
First Online: 3 October 2024
Declarations
:
: The need for ethics approval was waived by the Medical Ethics Committee of the Amsterdam UMC, location AMC. Participants provided written informed consent prior to the focus group discussions or interviews.
: The consent to publish the results of the study is included in the informed consent.
: EE is a sub-investigator involved in a pre-marketing study with Sanofi Genzyme. MB was a sub-investigator in the Lysogene gene therapy study for MPS III (NCT02053064). ML and CH are involved in pre-marketing studies with Sanofi Genzyme, Protalix, Cheisi and Idorsia. BS was involved inpre-marketing studies with Protalix, Cheisi, Sanofi-Genzyme and Reneo Pharmaceuticals.
